1. Over 1 million treated with highly effective hepatitis C medicines. WHO. www.who.int/mediacentre/news/releases/2016/hepatitis-c-medicines/en/.
2. Natco tries to block hepatitis C patent in India. GaBI. www.gabionline.net/Generics/General/Natco-tries-to-block-hepatitis-C-patent-in-India.
3. Japan approves first all-oral, interferon- and ribavirin-free hepatitis C treatment, Daklinza®(daclatasvir) and Sunvepra®(asunaprevir) dual regimen. BMS. http://news.bms.com/press-release/japan-approves-first-all-oral-interferon-and-ribavirin-free-hepatitis-c-treatment-dakl.
4. Merck bids $3.8 billion for an edge in hepatitis. The New York Times. http://dealbook.nytimes.com/2014/06/09/merck-to-acquire-idenix-pharmaceuticals/?_php=true&_type=blogs&_php=true&_type=blogs&_php=true&_type=blogs&_r=3&
5. European Medicines Agency recommends approval of Daklinza in chronic hepatitis C. www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2014/06/news_detail_002133.jsp&mid=WC0b01ac058004d5c1.